You can buy Enasidx at the lowest price at Nextgen.ooo online pharmacy. Enasidenib is an oral drug for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with specific mutations in the isocitrate dehydrogenase 2 (IDH2) gene, which is found in 12% to 20% of adult patients with AML. Patients eligible for this treatment are selected by testing for IDH2 mutations in their blood or bone marrow. This small molecule acts as an allosteric inhibitor of the mutant IDH2 enzyme, preventing cell growth, and also blocks several other enzymes that play a role in abnormal cell differentiation. Enasidenib was approved by the US Food and Drug Administration on August 1, 2017.
 
Wild-type IDH proteins play a critical role in the Krebs cycle, where they catalyze the oxidative decarboxylation of isocitrate to α-ketoglutarate. In comparison, mutant forms of the IDH2 enzyme mediate neomorphic activity and catalyze the reduction of α-KG to the (R) enantiomer 2-hydroxyglutarate, which is associated with DNA and histone hypermethylation, altered gene expression, and block in hematopoietic progenitor cell differentiation. Enasidenib primarily targets the IDH2 mutant variants R140Q, R172S, and R172K with higher potency than the wild-type form of the enzyme. Enzyme inhibition results in decreased 2-hydroxyglutarate (2-HG) levels and promotes proper differentiation and clonal proliferation of myeloid-derived cells.